VRDN

Viridian Therapeutics Inc. (VRDN) | Rumor.io

Viridian Therapeutics

VRDN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,646

Bullish sentiment (50-day avg)79%

Price to earnings ratio-6.2

Market capitalization2.3B

Earnings per share-3.4

Dividend yield (TTM)—

Revenue (annual)70.8M

Net income (annual)-342.6M

Social

What share of all stock conversation is about VRDN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 6

Viridian Therapeutics' revenue jumped 279% in the latest quarter, but still only amounted to $284,000 in sales over three months, with the operating loss widening.
The company's first doses of Lumvoa were administered in July, and patient enrollment forms indicate broad and strong physician demand, with progress ahead of schedule.
Viridian Therapeutics stock has shown strong momentum, with a 6.64% gain after beating Q2 sales expectations, and a short ratio at 8.20 indicating potential for a squeeze.

Generated by AI

Sentiment

Of the messages about VRDN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +27.78	88.89% +3.78
Bearish	—	—	0% -27.78	11.11% -3.78

Bullish· Jun 29

Viridian Therapeutics' ($VRDN) recent FDA approval for its first commercial drug, Lumvoa, is seen as a major milestone, with the stock gapping up on the news and potentially reaching $35.
The company's strong pipeline, including subcutaneous elegrobart, is expected to drive growth and dominate the TED market, with analysts reiterating buy ratings and maintaining high price targets.
With a large cash reserve and debt-free status, Viridian Therapeutics is well-positioned to achieve critical mass by 2027, making it a promising long-term growth play.

Bearish· May 6

The company's shares plummeted over 32% after unveiling Phase 3 results for elegrobart in active thyroid eye disease patients, with one analyst calling the results "positive, but lackluster".
The asset's subcutaneous injections may face competition from AMGN's IV Tepezza, potentially de-risking the approvability of elegrobart and setting the stage for a compelling, infrequent SC product offering in TED.
The sell pressure on the asset could be due to the $250MM convertible note offering, which may lead to current largest inst holders selling common stock to buy convertible notes.

Generated by AI

Topics

Of the messages about VRDN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	77.17%
Technical Analysis	—	—	0%	5.18%
Analysts	—	—	14.29%	5.38%
Controversies	—	—	0%	0.8%
Earnings	—	—	0%	10.67%
Macro	—	—	0%	0.8%

Announcements· Jun 29

Viridian Therapeutics' ($VRDN) Lumvoa has been approved by the FDA for the treatment of thyroid eye disease, with positive phase 3 results showing rapid and durable reductions in key symptoms.
The approval marks a major commercial milestone for the company, with Lumvoa being the first FDA-approved treatment for thyroid eye disease that includes data for both active and chronic forms of the illness.
Viridian plans to launch Lumvoa immediately, with a subcutaneous version of the drug on track for a biologics license application (BLA) submission in Q1 2027, and the company hosting a conference call and webcast on June 29 to discuss the approval.

Technical Analysis· Oct 28

$VRDN has a potential dip opportunity around $1.10-$1.15 support, with a rinse and repeat strategy applicable.
The chart is key for $VRDN, with a bearish day overall and a reversal low 1 support on watch.
$VRDN's double attempt to breach $1.30s failed, with a MACD divergence and curling down at these levels, potentially leading to a sell-off to break $1.00 tomorrow.

Generated by AI

Community

Of the messages about VRDN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	76.92%	81.74%	60.46%
Newcomers	—	23.08%	18.26%	39.54%

Regulars· Mar 30

Viridian Therapeutics' ($VRDN) stock price has dropped despite positive REVEAL-1 trial results, with some analysts expecting the company to face challenges in competing with Tepezza.
Regulars are discussing the potential impact of Viridian's Phase 3 trial results on the company's regulatory approval process and its prospects for competing with Tepezza.
The positive REVEAL-1 trial results have been announced, but the stock price has not reflected the expected positive outcome, with some analysts citing concerns about the company's regulatory position.

Newcomers· Jun 29

The newcomers are focused on the FDA approval of Viridian Therapeutics' drug Lumvoa, which sparked a pre-market rally in the company's stock.
They are also discussing the potential for Viridian Therapeutics to reach analyst targets of up to $35, making it a potential growth play for July.
The newcomers are concerned about the launch of Lumvoa, with some expressing uncertainty about how the market will react, and others planning to pursue integration between ISSCA AI and the company's CELLGENIC biologics operation.

Generated by AI

News

Weekly Note: Revisiting Viridian Therapeutics: Two Shots At An IGF-1R Franchise, Priced For One (NASDAQ:VRDN)

PHVS, UNCY, BHVN, CYTK, KURA, GRCE, INSM, RARE, CELC, RCKT_________________________________________________BUY | 12-month price target $31 (+51%) | Lumvoa...

2d agoSeeking Alpha

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark

7d agoYahoo Finance

Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN)

Viridian Therapeutics aims to leverage its infrastructure for both Lumvoa and elegrobart, potentially improving franchise economics. Read more on VRDN.

12d agoSeeking Alpha

Sling Therapeutics raises $123 million to advance thyroid eye disease drug

13d agoReuters

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

26d agoBenzinga

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

27d agoYahoo Finance

Also Discussed

Investors talking about VRDN also mention

#	Name	Attention
1	Arvinas, Inc.ARVN	0%+0
2	Vera Therapeutics Inc.VERA	0%new
3	SLNO - Soleno Therapeutics, Inc.	——
4	GENE - Genetic Technologies Limited	——
5	Mineralys Therapeutics, Inc.MLYS	0%+0
6	AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETFSIXD	0%0
7	PeakShares Sector Rotation ETFPSTR	0%new
8	Natuzzi S.p.A. ADRNTZ	0%0
9	SINO - Singularity Future Technology Ltd.	——
10	Oncolytics Biotech Inc.ONCY	0%0

Viridian Therapeutics Inc.

Healthcare
Biotechnology

Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease. The company’s current pipeline centers on antibody-based programs designed to target validated disease pathways, including intravenous and subcutaneous candidates for thyroid eye disease and additional assets aimed at autoimmune conditions. Viridian Therapeutics also advances FcRn inhibitor programs, expanding its work across immunology-focused indications. The company operates in the biotechnology and specialty therapeutics market, where it contributes to the development of differentiated medicines for patients with serious conditions that have limited treatment options. Headquartered in Waltham, Massachusetts, Viridian Therapeutics combines antibody discovery and protein engineering to support its research, clinical development, and future commercialization efforts.

Website

Location

221 Crescent Street

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about VRDN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 6

Viridian Therapeutics' revenue jumped 279% in the latest quarter, but still only amounted to $284,000 in sales over three months, with the operating loss widening.
The company's first doses of Lumvoa were administered in July, and patient enrollment forms indicate broad and strong physician demand, with progress ahead of schedule.
Viridian Therapeutics stock has shown strong momentum, with a 6.64% gain after beating Q2 sales expectations, and a short ratio at 8.20 indicating potential for a squeeze.

Generated by AI

Sentiment

Of the messages about VRDN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +27.78	88.89% +3.78
Bearish	—	—	0% -27.78	11.11% -3.78

Bullish· Jun 29

Viridian Therapeutics' ($VRDN) recent FDA approval for its first commercial drug, Lumvoa, is seen as a major milestone, with the stock gapping up on the news and potentially reaching $35.
The company's strong pipeline, including subcutaneous elegrobart, is expected to drive growth and dominate the TED market, with analysts reiterating buy ratings and maintaining high price targets.
With a large cash reserve and debt-free status, Viridian Therapeutics is well-positioned to achieve critical mass by 2027, making it a promising long-term growth play.

Bearish· May 6

The company's shares plummeted over 32% after unveiling Phase 3 results for elegrobart in active thyroid eye disease patients, with one analyst calling the results "positive, but lackluster".
The asset's subcutaneous injections may face competition from AMGN's IV Tepezza, potentially de-risking the approvability of elegrobart and setting the stage for a compelling, infrequent SC product offering in TED.
The sell pressure on the asset could be due to the $250MM convertible note offering, which may lead to current largest inst holders selling common stock to buy convertible notes.

Generated by AI

Topics

Of the messages about VRDN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	77.17%
Technical Analysis	—	—	0%	5.18%
Analysts	—	—	14.29%	5.38%
Controversies	—	—	0%	0.8%
Earnings	—	—	0%	10.67%
Macro	—	—	0%	0.8%

Announcements· Jun 29

Viridian Therapeutics' ($VRDN) Lumvoa has been approved by the FDA for the treatment of thyroid eye disease, with positive phase 3 results showing rapid and durable reductions in key symptoms.
The approval marks a major commercial milestone for the company, with Lumvoa being the first FDA-approved treatment for thyroid eye disease that includes data for both active and chronic forms of the illness.
Viridian plans to launch Lumvoa immediately, with a subcutaneous version of the drug on track for a biologics license application (BLA) submission in Q1 2027, and the company hosting a conference call and webcast on June 29 to discuss the approval.

Technical Analysis· Oct 28

$VRDN has a potential dip opportunity around $1.10-$1.15 support, with a rinse and repeat strategy applicable.
The chart is key for $VRDN, with a bearish day overall and a reversal low 1 support on watch.
$VRDN's double attempt to breach $1.30s failed, with a MACD divergence and curling down at these levels, potentially leading to a sell-off to break $1.00 tomorrow.

Generated by AI

Community

Of the messages about VRDN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	76.92%	81.74%	60.46%
Newcomers	—	23.08%	18.26%	39.54%

Regulars· Mar 30

Viridian Therapeutics' ($VRDN) stock price has dropped despite positive REVEAL-1 trial results, with some analysts expecting the company to face challenges in competing with Tepezza.
Regulars are discussing the potential impact of Viridian's Phase 3 trial results on the company's regulatory approval process and its prospects for competing with Tepezza.
The positive REVEAL-1 trial results have been announced, but the stock price has not reflected the expected positive outcome, with some analysts citing concerns about the company's regulatory position.

Newcomers· Jun 29

The newcomers are focused on the FDA approval of Viridian Therapeutics' drug Lumvoa, which sparked a pre-market rally in the company's stock.
They are also discussing the potential for Viridian Therapeutics to reach analyst targets of up to $35, making it a potential growth play for July.
The newcomers are concerned about the launch of Lumvoa, with some expressing uncertainty about how the market will react, and others planning to pursue integration between ISSCA AI and the company's CELLGENIC biologics operation.

Generated by AI

Viridian Therapeutics

Social

Aug 6

Bullish· Jun 29

Bearish· May 6

Announcements· Jun 29

Technical Analysis· Oct 28

Regulars· Mar 30

Newcomers· Jun 29

Weekly Note: Revisiting Viridian Therapeutics: Two Shots At An IGF-1R Franchise, Priced For One (NASDAQ:VRDN)

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN)

Sling Therapeutics raises $123 million to advance thyroid eye disease drug

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Also Discussed

Viridian Therapeutics Inc.

Company Information

Location

Weekly Note: Revisiting Viridian Therapeutics: Two Shots At An IGF-1R Franchise, Priced For One (NASDAQ:VRDN)

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN)

Sling Therapeutics raises $123 million to advance thyroid eye disease drug

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Also Discussed

Social

Aug 6

Bullish· Jun 29

Bearish· May 6

Announcements· Jun 29

Technical Analysis· Oct 28

Regulars· Mar 30

Newcomers· Jun 29